DIM
ALNY icon

Delta Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Delta Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,985
Closed -$2.66M – 139
2020
Q2 		$2.66M Buy
+17,985
New +$2.42M 1.11% 27
2020
Q1 		– Sell
-20,500
Closed -$2.36M – 108
2019
Q4 		$2.36M Buy
+20,500
New +$2.04M 0.86% 35

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Delta Investment Management's ALNY Position: Q3 2020 in Review

Delta Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 17,985 shares — an estimated $2.66M sold.

Delta Investment Management first reported a position in ALNY in Q4 2019 and held it in 2 quarters. The position peaked at $2.66M in Q2 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • Delta Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Delta Investment Management sold 17,985 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $2.66M.
  • Delta Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Delta Investment Management's Alnylam Pharmaceuticals position peaked at $2.66M in Q2 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Delta Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.